NEWS

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Hemispherian raises seed funding for novel cancer therapeutics

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Atriva Therapeutics Announces Changes to Management

Atriva Therapeutics Announces Changes to Advisory Board

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Aptamer Group on BBC Look North 17th June 2020

LightOx May 2020

Britten kopen farmabedrijf Synthon uit Nijmegen

Dringend gezocht: nieuwe antibiotica

Aanval op het bestverkochte medicijn ter wereld

De lamme laten lopen, de blinde laten zien

Japans Itochu steekt €10 mln in Waals stamcellenbedrijf

Novartis maakt Rotterdams medicijn zes keer duurder